Details

Autor(en) / Beteiligte

• Pender, Alexandra
• Jones, Robin L

Titel

Olaratumab: a platelet-derived growth factor receptor-[alpha]-blocking antibody for the treatment of soft tissue sarcoma

Ist Teil von

• Clinical pharmacology: advances and applications, 2017-01, Vol.9, p.159

Ort / Verlag

Dove Medical Press Limited

Erscheinungsjahr

2017

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase lb/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-[alpha] (PDGFR[alpha])-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable STS. In this review, we discuss the potential role of PDGFR[alpha] signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas. Keywords: olaratumab, sarcoma, PDGFR